Disparity Expression of GammaH2AX in Papillary Thyroid Cancer and Nodular Goiter

作者:Hu, Sisi; Zhang, Gu; Xu, Jiajie; Zhu, Xin; Lu, Xiaoxiao; Jiang, Liehao; Wang, Qingliang; Hou, Xiuxiu; Cao, Jun; Ge, Minghua*
来源:Clinical Laboratory, 2014, 60(12): 2031-2037.
DOI:10.7754/Clin.Lab.2014.140603

摘要

Background: H2AX, one of the variants of histone H2A with conserved sequence, plays a vital role in maintaining genomic stability. DNA double-strand break (DSB) induces H2AX phosphorylation (gamma H2AX). Growing evidence indicated gamma H2AX was linked to thyroid disease. However, the precise expression of gamma H2AX in papillary thyroid carcinoma (PTC) and nodular goiter was unknown. In this study, the gamma H2AX expression in PTC and nodular goiter and the significance of the aberrant expression were investigated. Methods: The gamma H2AX expression level was evaluated by immunohistochemistry staining in 140 specimens with thyroid diseases (30 cases of nodular goiter, 30 cases of PTC, and 80 cases of FTC coexisting with nodular goiter). The possible relationships between gamma H2AX expression and patients' clinicopathological characteristics were analyzed. Results: In the set of nodular goiter, 20.0% (6/30) of nodular goiter component and 10.0% (3/30) of normal adjacent tissues exhibited high expression of gamma H2AX (p > 0.05). In the set of PTC, 70.0% (21/30) of FTC component and 0.0% (0/30) of normal adjacent tissues showed high expression of gamma H2AX (p <0.05). In the set of FTC coexisting with nodular goiter, 95.0% (76/80) of PTC component, 12.5% (10/80) of nodular goiter component, and 8.8% (7/80) of normal adjacent specimens showed high expression of gamma H2AX (p <0.05). 85.5% (65/76) of FTC patients with lymph node metastasis were found to have a high expression level of gamma H2AX, and the proportion was lower than that in patients without lymph node metastasis (34/34, 100.0%) (p = 0.003). High gamma H2AX expression was also found in 76.2% (16/21) of stage IV patients and the proportion was lower than that in stage I - III patients (83/89, 93.3%) (p = 0.034). No statistically significant correlation was found between gamma H2AX expression level and other clinicopathological features, including age, gender, capsular invasion, tumor size, tumor focus number, distant metastasis, and T status. Conclusions: gamma H2AX expression was increased in FTC patients, while nodular goiter and normal adjacent tissues exhibited no statistically significant difference in gamma H2AX expression. gamma H2AX expression had a negative correlation with TNM stage and lymph node metastasis. gamma H2AX seems to play a more critical role in early-stage FTC rather than late-stage FTC and might inhibit lymph node metastasis.